Autoantibodies against type I IFNs in patients with critical influenza pneumonia


1St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY; 2Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France; 3Université Paris Cité, Imagine Institute, Paris, France; 4CIRI, Centre International de Recherche en Infectiologie - Team VirPath, Univ Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS Lyon, Lyon, France; 5Dept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY; 6Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY; 7Dept. of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France; 8Sigma Therapeutics SAS, Lyon, France; 9VirNext, Faculty of Medicine RTH Laennec, Claude Bernard Lyon 1 University, Lyon, University, Lyon, France; 10Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France; 11Dept. of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; 12Pathology Advanced Translational Research Unit, Dept. of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA; 13Center for Biomedical Research in Infectious Diseases Networks (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain; 14Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocio University Hospital, Seville, Spain; 15Institute of Biomedicine of Seville (IBIS), CSIC, University of Seville, Seville, Spain; 16Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; 17Dept. of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain; 18University of Barcelona, Barcelona, Spain; 19Infectious Diseases, Microbiology Unit, Virgen Macarena University Hospital, Seville, Spain; 20Etablissement Français Du Sang, La Plaine-Saint Denis, Saint-Denis, France; 21University of Paris Cite, University of Paris-Saclay, UVSQ, INSERM U8531, Villejuif, France; 22University of Bordeaux, INSERM, Bordeaux Population Health Center, UMR1219, Bordeaux, France; 23Laboratory for Innate Errors of Immunity, Dept. of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; 24Dept. of Pediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent, PID Research Laboratory, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium; 25Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; 26Immunodeficiencies Unit, Hospital October 12, Research Institute Hospital October 12, School of Medicine, Complutense University, Madrid, Spain; 27Pediatrics Service, Hematology and Oncology Unit, University Hospital October 12, Madrid, Spain; 28Laboratory of Immunodeficiency, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece; 29Dept. of Immunology, University Hospital of Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain; 30Dept. of Clinical Sciences, University Hospital Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain; 31CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; 32Dept. of Internal Medicine, University Hospital University Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain; 33Dept. of Respiratory Diseases, University Hospital 12 October, Madrid, Spain; 34Dept. of Respiratory Diseases, Hospital Clinico de Valencia, Valencia, Spain; 35Instituto de Biomedicina y de Translational Medicine, University of Tartu, Tartu, Estonia; 36Dept. of Medicine, Division of Infectious Diseases, Ichsan School of Medicine at Mount Sinai, New York, NY; 37The Tisch Cancer Institute, Ichsan School of Medicine at Mount Sinai, New York, NY; 38Dept. of Pathology, Medical and Surgical Sciences, Ichsan School of Medicine at Mount Sinai, New York, NY; 39Hoffman Hughes Medical Institute, New York, NY.

*Q. Zhang, A. Pizzorno, and L. Miorin contributed equally to this paper; **P. Bastard, A. Gervais, T. Le Voyer, and L. Bizien contributed equally to this paper; ***K. Kisand, A. Piel, E. Jouangy, L. Abel, and A. Cobat contributed equally to this paper; ****S. Trouillet-Assant, A. García-Sastre, and J.-L. Casanova contributed equally to this paper. Correspondence to Jean-Laurent Casanova: casanova@rockefeller.edu; Qian Zhang: qzhang02@rockefeller.edu

COVID Human Genetic Effort, Etablissement Français du Sang Study Group, Constances Cohort, 3C-Dijon Study, Cerba HealthCare Group, Lyon Antigrippe Working Group, and REIPI INF Working Group member names and affiliations are listed at the end of the end of the PDF.

© 2022 Zhang et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10<sup>−4</sup>), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10<sup>−5</sup>), especially those <70 yr old (OR = 139.9, P = 3.1 × 10<sup>−10</sup>). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ~5% of cases of life-threatening influenza pneumonia in patients <70 yr old.

Introduction

Seasonal influenza viruses (influenza A and B viruses [IAV and IBV]) infect ~18% of unvaccinated people each winter, ~17% of whom require medical attention (Hayward et al., 2014). Most unvaccinated infected individuals present with only asymptomatic infection or self-limited disease, but seasonal influenza nevertheless accounts for ~400,000 deaths from respiratory causes per year worldwide (Iuliano et al., 2018; Paget et al., 2019; Krammer et al., 2018) and ~10% of admissions and deaths from respiratory disease in hospitals (Cromer et al., 2014). Mortality rates are even higher for virulent, pandemic influenza viruses (Krammer et al., 2018). Why do a minority of infected individuals suffer from life-threatening seasonal influenza, whereas the majority do not? Different viral strains can explain year-to-year or region-to-region differences in mortality (Medina and Garcia-Sastre, 2011; Tschirner and Garcia-Sastre, 2011), but not interindividual variability within a given region and time period (Casanova and Abel, 2020, 2021a, 2021b, 2022; Zhang et al., 2022). Efforts have been made to identify human epidemiological risk factors. Aging is the major epidemiological determinant of death from influenza infection (Cromer et al., 2014; Paget et al., 2019; Iuliano et al., 2018; Krammer et al., 2018). Despite differences in overall mortality between the 32 countries with various levels of vaccination coverage studied, it is clear that people aged 65–75 yr, and those >75 yr old, are 7–38 and 24–249 times more likely, respectively, to die from respiratory influenza infection than people <65 yr old (Iuliano et al., 2018). The age-dependent increase in the risk of death, and the sharp increase in people >65 yr old in particular, remain unexplained, but has also been reported for other respiratory viruses, including adenovirus, respiratory syncytial virus (Watson and Wilkinson, 2021), and SARS-CoV-2 (Piroth et al., 2020), suggesting the possibility of shared immunological mechanisms. A few comorbid conditions, such as chronic pulmonary diseases, are associated with life-threatening influenza (Cromer et al., 2014). Both anti-influenza vaccination and infections with influenza viruses confer some protection against specific and, to a lesser extent, cross-reactive influenza viruses (Krammer et al., 2018; Kostova et al., 2013). However, a lack of immune memory is not, in itself, sufficient to cause critical influenza, as demonstrated by patients with inherited and acquired deficiencies of T and B cell adaptive immunity, whose impaired antibody responses to the influenza vaccine do not seem to create a predisposition to critical influenza (Zhang, 2020). Most, if not all, life-threatening cases of influenza in vaccinated and unvaccinated individuals, including those >65 yr old, remain unexplained at the molecular and cellular levels.

A first breakthrough came from human genetic studies of rare children with life-threatening influenza pneumonia. In 2015, we reported autosomal recessive (AR) IRF7 deficiency in an otherwise healthy 7-yr-old girl who had suffered from life-threatening influenza pneumonia at the age of 3 yr (Ciancanelli et al., 2015). She has since remained well with only annual influenza vaccinations and vaccination against COVID-19 for prophylaxis. Two other patients with IRF7 deficiency suffering from severe influenza pneumonia at the ages of 7 mo and 14 yr have recently been reported (Campbell et al., 2022). IRF7 is a transcription factor required for the production of the 17 type I IFNs and three type III IFNs, with IFN-β not being strictly IRF7 dependent in some cell types (Ciancanelli et al., 2015; Zhang et al., 2020b; Campbell et al., 2022). Plasmacytoid dendritic cells from these patients produced no type I and III IFNs other than IFN-β in response to IAV (Ciancanelli et al., 2015; Campbell et al., 2022). Moreover, a 2-yr-old child with AR IRF9 deficiency (Hernandez et al., 2018); three children with autosomal dominant TLR3 deficiency (Lim et al., 2019), aged 5 wk and 5 and 9 yr; three children with AR STAT1 deficiency, including two aged 1 mo and one aged 6 mo (Le Voyer et al., 2021); and a 10-mo-old child with AR STAT2 deficiency (Freij et al., 2020) have all been reported to have suffered from life-threatening influenza pneumonia. TLR3 is an endosomal sensor of dsRNA that controls tonic type I IFN levels in at least some nonhematopoietic cells (Gao et al., 2021), whereas STAT1, STAT2, and IRF9 are the three components of the type I and III IFN-driven ISGF3 transcription factor (Zhang, 2020). Both IRF7- and TLR3-deficient respiratory epithelial cells (RECs) derived from patients’ induced pluripotent stem cells fail to control IAV replication (Lim et al., 2019; Ciancanelli et al., 2018), a phenotype rescued by exogenous type I or III IFN. These five genetic etiologies of life-threatening influenza pneumonia thus impair type I and III IFN immunity to IAV. These cases revealed the indispensable role of human intrinsic (TLR3, IRF7, IRF9, STAT1, and STAT2 in RECs, in which the virus replicates) and innate (IRF7 in plasmacytoid dendritic...
cells, in which the virus does not replicate) type I and III IFN immunity in host defense against influenza (Casanova and Abel, 2021b, 2022; Duncan et al., 2021; Manry et al., 2022; Zhang et al., 2022).

The genetic study of critical influenza pneumonia led to that of critical COVID-19 pneumonia (Casanova and Abel, 2021b, 2022; Zhang et al., 2022). The COVID Human Genetic Effort (http://www.covidhge.com; Casanova et al., 2020) found in-born errors of TLR3-dependent or -independent type I IFN immunity, including not only AR IRF7 deficiency but also AR IFNAR1 deficiency, in previously healthy patients with critical COVID-19 (Zhang et al., 2020b, 2022, Casanova and Abel, 2021b, 2022; Abolhassani et al., 2022; Campbell et al., 2022). Following on from the 1984 description of autoantibodies (auto-Abs) against type I IFNs in a single patient with disseminated zoster (Pozzetto et al., 1984), we showed that preexisting auto-Abs neutralizing type I IFNs underlie ≥15% of cases of life-threatening COVID-19 pneumonia (Bastard et al., 2020; Bastard et al., 2021a; Zhang et al., 2022; Puel et al., 2022) and 30% of severe adverse reactions to the yellow fever vaccine (Bastard et al., 2021c). These findings have since been widely replicated (Abers et al., 2021; Acosta-Ampudia et al., 2021; Bastard et al., 2021d; Chang et al., 2021; Chauvineau-Grenier et al., 2021; Goncalves et al., 2021; Koning et al., 2021; Bastard et al., 2021a; Zhang et al., 2022; Puel et al., 2022) and auto-Abs neutralizing type I IFNs underlie life-threatening influenza (Bello-Rivero et al., 2004; Meager et al., 2003). Plasma containing auto-Abs neutralizing type I IFNs were detected in 1% of patients with COVID-19 (Zhang et al., 2020b, 2022, Casanova and Abel, 2021a). These auto-Abs are the second most common determinant of COVID-19 death after age (Zhang et al., 2020a, 2022; Bastard et al., 2021a; Casanova and Abel, 2021b, 2022; Manry et al., 2022; Puel et al., 2022). We therefore hypothesized that auto-Abs neutralizing type I IFNs might also underlie life-threatening influenza pneumonia.

**Results**

**Auto-Abs neutralizing IFN-α2 in 13 of 279 patients (4.7%) with critical influenza**

We recruited 279 patients from Belgium (31), Greece (5), Spain (40, including some cases described previously; Lopez-Rodriguez et al., 2016; Herrera-Ramos et al., 2014), Israel (1), and France (202) who had been hospitalized for critical influenza pneumonia, as defined by admission to an intensive care unit (ICU) for acute respiratory distress syndrome (ARDS) following a diagnosis of influenza and treatment with invasive or noninvasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), between 2012 and 2021. 32 of the 279 patients died, and 247 survived. The patients were between 7 d and 94 yr old; 52% were male and 48% were female (Fig. 1 A).

We searched for circulating auto-Abs neutralizing type I IFNs in luciferase-based neutralization assays, as previously performed in patients with COVID-19 pneumonia and healthy donors (Bastard et al., 2021a). We identified 13 patients with neutralizing auto-Abs (P1–13), including 6 patients with auto-Abs neutralizing high concentrations (10 ng/ml) of both IFN-α2 and IFN-ω, 2 patients with auto-Abs neutralizing high concentrations of IFN-α2 and low concentrations (100 pg/ml) of IFN-ω, 1 patient with auto-Abs neutralizing high concentrations of IFN-α2 only, 1 patient with auto-Abs neutralizing low concentrations of both IFN-α2 and IFN-ω, and 3 patients with auto-Abs neutralizing low concentrations of IFN-α2 only (Table 1 and Fig. 1 B). None of the patients had auto-Abs neutralizing 10 ng/ml IFN-β. We previously showed that auto-Abs against IFN-α2 neutralized the other 12 forms of IFN-α (Bastard et al., 2020; Bastard et al., 2021a). Finally, we searched for auto-Abs against type III IFNs in 5 of the 13 patients with auto-Abs against type I IFNs. One of them (P3) had auto-Abs neutralizing IFN-λ1/IL-29 (half-maximal inhibitory concentration is 1/960 dilution for 12.5 pg/ml IL-29), but neither IFN-λ2 (IL-28A) nor IFN-λ3 (IL-28B; not depicted).

**Most patients with auto-Abs are male and <70 yr of age**

The 13 auto-Ab–positive patients comprised 10 (77%) male patients and 3 female patients (23%); 1 of these patients was a child (<16 yr, 7.7%), 9 were adults aged 16–69 yr (69%), and 3 were elderly (≥70 yr old, 23%; Fig. 1 C). None of the auto-Ab–positive patients had been vaccinated against influenza in the year preceding disease onset. As in patients with critical COVID-19 and auto-Abs against type I IFNs (Bastard et al., 2021a; Bastard et al., 2020), the population of auto-Ab–positive patients with life-threatening influenza was mostly male, although this was not statistically significant. Indeed, 6.9% of male patients with critical influenza were auto-Ab positive, whereas only 2.2% of female patients with critical influenza were auto-Ab positive. The auto-Abs detected were of a similar nature to those observed in patients with critical COVID-19 pneumonia, with most patients having auto-Abs neutralizing high concentrations of IFN-α2 (~70% in the influenza cohort and ~60% in the COVID-19 cohort), a minority of patients having auto-Abs against IFN-ω only, and even fewer auto-Abs against IFN-β only (Table 1). We also recruited 38 patients with clinically diagnosed mild influenza infection who did not require hospitalization during the
The same period, including 14 from Spain and 24 from Greece. These patients were 18–80 yr old, and 57.9% were men. None of these 38 patients had auto-Abs neutralizing either high or low concentrations of IFN-α2, IFN-ω, or IFN-β (Fig. 1, A and B). Overall, auto-Abs neutralizing IFN-α2 alone or with IFN-ω were found in 4.7% of patients with life-threatening influenza pneumonia, 5.5% of patients <70 yr old, 6.9% of men with life-threatening influenza, and 7.5% of men <70 yr old.

**Individuals <70 yr old with auto-Abs against type I IFNs are at risk of critical influenza**

We previously tested 34,159 healthy men and women aged 20–100 yr to estimate the prevalence of auto-Abs neutralizing type I IFNs in the uninfected general population (Bastard et al., 2021a). We further tested 1,065 healthy children, 12 (1.1%) of whom were found to be auto-Ab positive (Bastard et al., 2022b). We then compared the prevalence of auto-Abs against type I IFN between patients with life-threatening influenza and the general population. We first compared the prevalence of auto-Abs neutralizing at least low concentrations of IFN-α2 and/or IFN-ω, which were present in the largest number of patients (13 carriers among the 272 individuals tested, 4.8%) and members of the general population, in a sex- and age-adjusted Firth’s bias-corrected logistic regression analysis. We found a general enrichment in these auto-Abs in patients with critical influenza pneumonia relative to the general population (2.2%; odds ratio [OR] = 2.3, 95% confidence interval [CI] 1.2–3.9, P = 0.01; Fig. 2 A). We then investigated the age effect in greater detail. We found a significant interaction between age, classified into two groups (younger individuals <70 yr old, and older individuals ≥70 yr old).
## Table 1. Patients with auto-Abs neutralizing type I IFNs and influenza pneumonia

<table>
<thead>
<tr>
<th>Patient</th>
<th>Auto-Abs</th>
<th>Gender</th>
<th>Age (yr)</th>
<th>Residence</th>
<th>Influenza pneumonia severity</th>
<th>Viral strain</th>
<th>Vaccinated</th>
<th>Clinical history</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IFN-α (10 ng/ml)</td>
<td>IFN-α (100 ng/ml)</td>
<td>IFN-ω (10 ng/ml)</td>
<td>IFN-ω (100 ng/ml)</td>
<td>IFN-β (10 ng/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>M 73</td>
<td>Greece</td>
<td>Bilateral lung infiltrates, noninvasive mechanical ventilation</td>
<td>IAV (H3)</td>
</tr>
<tr>
<td>P2</td>
<td>+</td>
<td>NA</td>
<td>+</td>
<td>NA</td>
<td>−</td>
<td>F 67</td>
<td>Belgium</td>
<td>Admitted to ICU, noninvasive ventilation for 5 d</td>
<td>IAV</td>
</tr>
<tr>
<td>P3</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>M 28</td>
<td>Belgium</td>
<td>Admitted to ICU, invasive ventilation for 10 d</td>
<td>IAV</td>
</tr>
<tr>
<td>P4</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>F 56</td>
<td>Spain</td>
<td>ARDS</td>
<td>IAV (H1N1)</td>
</tr>
<tr>
<td>P5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>M 62</td>
<td>Spain</td>
<td>ARDS</td>
<td>IAV (H1N1)</td>
</tr>
<tr>
<td>P6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>M 62</td>
<td>France</td>
<td>Admitted to ICU, intubated</td>
<td>IAV</td>
</tr>
<tr>
<td>P7</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>M 55</td>
<td>France</td>
<td>Admitted to ICU, intubated</td>
<td>IAV</td>
</tr>
<tr>
<td>P8</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>M 70</td>
<td>France</td>
<td>Admitted to ICU, intubated</td>
<td>IAV</td>
</tr>
<tr>
<td>P9</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>M 40</td>
<td>France</td>
<td>Admitted to ICU, ARDS, intubated, ECMO</td>
<td>IAV (H1N1)</td>
</tr>
<tr>
<td>P10</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>M 6</td>
<td>Israel</td>
<td>Admitted to ICU, ARDS</td>
<td>IAV (H1N1)</td>
</tr>
<tr>
<td>P11</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>F 48</td>
<td>France</td>
<td>Admitted to ICU, intubated</td>
<td>IAV</td>
</tr>
<tr>
<td>P12</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>F 48</td>
<td>France</td>
<td>Admitted to ICU, intubated, ECMO</td>
<td>IAV</td>
</tr>
<tr>
<td>P13</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>M 39</td>
<td>France</td>
<td>Admitted to ICU</td>
<td>IAV</td>
</tr>
<tr>
<td>P14</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>M 55</td>
<td>Chile</td>
<td>Hospitalized with oxygen therapy</td>
<td>IAV</td>
</tr>
<tr>
<td>P15</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>M 39</td>
<td>France</td>
<td>Intubated for hypoxemia influenza pneumonia, with secondary bacterial infection, intubated</td>
<td>IAV (H1N1)</td>
</tr>
</tbody>
</table>
### Table 1. Patients with auto-Abs neutralizing type I IFNs and influenza pneumonia (Continued)

<table>
<thead>
<tr>
<th>Patient</th>
<th>Auto-Abs</th>
<th>Gender</th>
<th>Age (yr)</th>
<th>Residence</th>
<th>Influenza pneumonia severity</th>
<th>Viral strain</th>
<th>Vaccinated</th>
<th>Clinical history</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>P16</td>
<td>+ + + + +</td>
<td>F</td>
<td>1.3</td>
<td>Belgium</td>
<td>ARDS, intubated</td>
<td>IAV (H1N1)</td>
<td>No</td>
<td>Diarrhea after oral rotavirus vaccine and skin eruption after MMRV vaccine, autoimmune hemolytic anemia, autoimmune pancreatitis</td>
<td>Deceased</td>
</tr>
<tr>
<td>P17</td>
<td>+ + + + −</td>
<td>M</td>
<td>43</td>
<td>Chile</td>
<td>Admitted to ICU, intubated</td>
<td>IAV (H1)</td>
<td>No</td>
<td>Chikungunya (2015) in Colombia</td>
<td>Survived</td>
</tr>
<tr>
<td>P18</td>
<td>+ + + + −</td>
<td>M</td>
<td>64</td>
<td>Chile</td>
<td>Hospitalized with oxygen therapy</td>
<td>IAV (H3)</td>
<td>No</td>
<td>Dyslipidemia, infrarenal abdominal aortic aneurysm</td>
<td>Survived</td>
</tr>
<tr>
<td>P19</td>
<td>+ + + + −</td>
<td>M</td>
<td>81</td>
<td>Chile</td>
<td>Hospitalized</td>
<td>IAV (H3)</td>
<td>Yes</td>
<td>Diabetes</td>
<td>Survived</td>
</tr>
<tr>
<td>P20</td>
<td>+ + + + −</td>
<td>M</td>
<td>83</td>
<td>Spain</td>
<td>Hospitalized</td>
<td>IAV (H3)</td>
<td>Yes</td>
<td>Obesity, arterial hypertension, asthma</td>
<td>Survived</td>
</tr>
<tr>
<td>P21</td>
<td>+ + − + −</td>
<td>F</td>
<td>85</td>
<td>Chile</td>
<td>Admitted to ICU, intubated</td>
<td>IAV (H1)</td>
<td>No</td>
<td>Asthma, heart disease, diabetes</td>
<td>Survived</td>
</tr>
<tr>
<td>P22</td>
<td>+ + − − −</td>
<td>F</td>
<td>91</td>
<td>Spain</td>
<td>Hospitalized with oxygen therapy</td>
<td>IAV (H1N1)</td>
<td>No</td>
<td>Asthma, heart disease, diabetes</td>
<td>Survived</td>
</tr>
<tr>
<td>P23</td>
<td>− − + + −</td>
<td>M</td>
<td>8</td>
<td>Taiwan</td>
<td>Admitted to ICU with oxygen therapy</td>
<td>IAV</td>
<td>NA</td>
<td>Sister died of encephalitis due to IAV (H1N1)</td>
<td>Survived</td>
</tr>
</tbody>
</table>

*+, positive; −, negative; COPD, Chronic obstructive pulmonary disease; F, female; GI, gastrointestinal; M, male; NA, data not available; RSV, respiratory syncytial virus.*
old), and the presence of these auto-Abs. Indeed, the prevalence of auto-Abs was significantly higher in younger patients (5.7 vs. 1.1%, OR = 5.7, 95% CI 3.0–11.1, \( P = 2.2 \times 10^{-5} \)) with critical influenza than in the general population, whereas no significant enrichment was observed in older patients (3.1 vs. 4.4%, OR = 0.80, 95% CI 0.27–2.4, \( P = 0.68 \)), consistent with the distribution of auto-Ab prevalence across age groups (Fig. 2 A). In summary, these results suggest that auto-Ab–positive individuals <70 yr of age have a higher risk of developing critical influenza pneumonia than auto-Ab–negative individuals.

Risk of critical influenza according to the nature of the auto-Abs against type I IFNs

We then performed the same logistic regression analyses taking into account all combinations of auto-Abs based on the nature and concentration of type I IFNs neutralized. All combinations of auto-Abs neutralizing different concentrations of IFN-\( \alpha_2 \), with or without IFN-\( \omega \), were significantly associated with critical influenza, albeit to different extents (Fig. 2 B). The presence of auto-Abs neutralizing high concentrations of both IFN-\( \alpha_2 \) and IFN-\( \omega \) was associated with the highest risk of developing critical influenza in the overall sample (OR = 11.7, 95% CI 4.6–25.5, \( P = 1.3 \times 10^{-5} \)). The presence of auto-Abs neutralizing high concentrations of IFN-\( \alpha_2 \) only, low concentrations of both IFN-\( \alpha_2 \) and IFN-\( \omega \), or IFN-\( \alpha_2 \) only was associated with a three to five times higher risk of developing critical influenza (Fig. 2 B). Furthermore, the presence of auto-Abs neutralizing high concentrations of both IFN-\( \alpha_2 \) and IFN-\( \omega \) had an even stronger impact in the subsample of subjects <70 yr old (OR = 139.9, 95% CI 42.3–462.5, \( P = 3.1 \times 10^{-10} \)), and this effect was even more marked in men <70 yr old (OR = 167.3, 95% CI 33.3–840.2, \( P = 3.2 \times 10^{-7} \)). The presence of auto-Abs neutralizing high concentrations of IFN-\( \alpha_2 \) only or low concentrations of both IFN-\( \alpha_2 \) and IFN-\( \omega \) resulted in a 20–80 times higher risk of developing critical influenza in patients <70 yr, whereas the presence of auto-Abs neutralizing low concentrations of IFN-\( \alpha_2 \) only resulted in an almost seven times higher risk of developing critical influenza in patients <70 yr (Fig. 2 B). We identified no patients with auto-Abs neutralizing IFN-\( \omega \) only or IFN-\( \beta \), whereas these antibodies were found in 1.4 and 0.2% of the general population, respectively (Bastard et al., 2021a). The absence of such antibodies in the patients in our sample was probably due to the small size of the sample tested, but this finding nevertheless suggests that the presence of such antibodies in the general population does not confer a strong predisposition to critical influenza, if, indeed, it increases susceptibility at all. In summary, the risk of critical influenza increased with both the concentration and number of type I IFNs neutralized by the auto-Abs. These findings are consistent with those previously reported for patients with critical COVID-19 pneumonia (Bastard et al., 2021a).
The auto-Abs neutralized the antiviral function of type I IFNs in respiratory epithelial-like A549 cells infected with IAV. These findings suggested that auto-Abs might block the antiviral activity of type I IFNs against IAV in vivo. We tested this hypothesis by subjecting an REC line, A549, to pretreatment with IFN-α2, with or without patient plasma, before infecting the cells with IAV (Cal/09 virus expressing mCherry). We then determined the percentage of mCherry-positive cells with an imaging cytometer, as an indicator of IAV replication (shown as percentage infection). Serial titration showed that the minimum concentration of IFN-α2 required for robust antiviral activity was 20 pg/ml, which blocked ~40% of IAV infection. We found that plasma from auto-Ab-positive patients completely neutralized 20 pg/ml IFN-α2 at a dilution of 1:100, as shown by the IAV infection rate of 100% (Fig. 3 A). We then further diluted the patients’ plasma to titrate neutralization capacity. We found that, when diluted 1:10,000, plasma from four of the six patients tested still effectively blocked the antiviral activity of 20 pg/ml IFN-α2 (Fig. 3 A). Thus, the auto-Abs from the patients tested blocked the anti-IAV activity of type I IFNs in vitro, thereby facilitating viral replication. These findings also indicate that some patients have auto-Abs with such high titers and/or affinity that they can block the antiviral activity of type I IFNs at concentrations beyond the physiological range (≥20 pg/ml).

Overall, we found that auto-Abs against type I IFNs from patients with critical influenza pneumonia neutralized the protective function of type I IFNs against IAV in vitro. For six patients (two auto-Ab-positive and four auto-Ab-negative) from whom plasma samples were collected at multiple time points, we found that neutralization capacity remained stable for ≥4 wk after admission (Fig. 3 B), consistent with previous observations in patients with life-threatening COVID-19 and auto-Abs neutralizing type I IFNs (van der Wijst et al., 2021; Shaw et al., 2021).

Neutralizing auto-Abs block the antiviral function of type I IFNs in reconstituted human airway epithelia (HAE) infected with IAV

We tested the hypothesis that auto-Abs block the antiviral activity of type I IFNs against IAV in HAE grown in an air–liquid interface, which mimics the physiological environment for IAV and SARS-CoV-2 infections in primary human cells (Pizzorno et al., 2019; Pizzorno et al., 2020). We treated HAE cells with 2 ng/ml IFN-α2 (24 h before and 1 h after IAV infection) in the presence or absence of patient plasma (1:100 dilution) and infected the cells with IAV (H1N1 pdm09). IFN-α2 strongly inhibited viral replication, as indicated by the 50% tissue culture infectious dose (TCID₅₀) and M gene copy numbers (Fig. 4, A and B). We tested plasma from seven patients with critical influenza and auto-Abs neutralizing 10 ng/ml IFN-α in luciferase assays at a 1:10 dilution. Plasma from six of the seven patients blocked the antiviral activity of 2 ng/ml IFN-α2 at a 1:100 dilution. More importantly, IAV infection led to a decrease in transepithelial electrical resistance (TEER), a measurement of the integrity of the epithelial barrier. IFN-α2 treatment can protect the epithelial barrier from IAV, thereby maintaining TEER. Plasma from five of the seven patients with severe influenza tested blocked the protective function of IFN-α2 (Fig. 4 C). Thus, IAV replication is associated with a loss of epithelial integrity, whereas type I IFN treatment is not. We also tested type III IFNs, including IFN-λ1 (IL-29), -λ2 (IL-28A), and -λ3 (IL-28B), in the same HAE.
system. We showed that 20 ng/ml type III IFNs also inhibited IAV replication and maintained normal TEER, although less effectively than IFN-α2 (Fig. 4, D and E). Interestingly, plasma from two patients did not block the protective function of IFN-α2, and one of these plasma samples did not block the antiviral activity of 2 ng/ml IFN-α2 completely when diluted 1:100 (Fig. 4, A–C). This was probably due to the high dilution of plasma in the HAE culture, to minimize nonspecific inhibition and toxicity due to the presence of human plasma. This observation may also suggest that differentiated RECs in the air–liquid interface and HEK293T cells respond differently in neutralization assays. We thus studied the biological consequences of auto-Abs in the HAE system with a Nanostring hybridization-based assay for multiplex mRNA detection and relative quantification for a panel of immune response genes. We found that IFN-α2 treatment or IAV infection induced the expression of IFN-stimulated genes (ISGs) in HAEs, and that this expression was blocked by auto-Ab–positive plasma from patients (Fig. 5, A and B). Consistent with TEER measurements, the levels of proinflammatory cytokines, including IL-6 and IL-1A, were higher in the presence of auto-Abs and high viral titers, further suggesting that viral replication led to epithelial damage and inflammation (Fig. 5 C). The levels of auto-Abs in the blood are correlated with, but not identical to, those in the respiratory tract (Lopez et al., 2021; Ziegler et al., 2021; Zhang et al., 2022), and the patient plasma used in the HAE culture was diluted 1:100, whereas a dilution of 1:10 was used for neutralization assays with HEK cells. In summary, the auto-Abs found in the patients with critical influenza blocked the antiviral function of IFN-α2 in respiratory models in vitro, increasing viral replication and tissue damage, together
with the production of proinflammatory cytokines by damaged cells.

**Auto-Abs neutralizing IFN-α2 and/or IFN-ω in five additional cohorts of patients hospitalized with influenza pneumonia**

In five other independent cohorts of 130 patients hospitalized for influenza pneumonia from Chile (82), Spain (45), France (1), Belgium (1), and Taiwan (1), including 84 patients requiring oxygen therapy (65%), screening for auto-Abs was performed by ELISA rather than neutralization assays (Fig. 6, A and B). Auto-Abs against IFN-α2 and/or IFN-ω were detected by ELISA in 27 patients (20%) aged 1–97 yr (65% of whom were male), including 15 patients requiring oxygen therapy. Because of the limited volumes of sample available, we tested only plasma samples...
from these ELISA-positive patients in our luciferase-based neutralization assays (Fig. 6 B). Only 10 of the 27 patients had neutralizing auto-Abs (P14–23): 3 with auto-Abs neutralizing high concentrations of IFN-α2, IFN-ω, and IFN-β (P14–16), 4 with auto-Abs neutralizing high concentrations of IFN-α2 and IFN-ω (P17–20), 1 with auto-Abs neutralizing high concentrations of IFN-α2 only (P21), 1 with auto-Abs neutralizing high concentrations of IFN-α2 only or IFN-ω only (P23; Fig. 6 C and Table 1). 8 of the 10 patients required oxygen, including 4 intubated and ventilated and 1 who died from critical pneumonia (P15). Overall, 7.7% of the patients in these 5 cohorts were present in almost 5% of patients hospitalised with influenza pneumonia in additional cohorts (P15). Overall, 7.7% of the patients in these 5 cohorts were hospitalised with influenza pneumonia (n = 130). (B) Patient plasma samples were tested by ELISA for auto-Abs against IFN-α2 and -ω. Patient plasma samples were diluted 1:50 before being added to plates coated with 2 μg/ml rhIFN-α or rhIFN-ω. HRP-conjugated goat anti-human IgG or IgA was added to final concentration of 2 μg/ml OD was measured. Each plasma sample was tested once. (C) Luciferase-based neutralization assay to detect auto-Abs neutralizing 10 ng/ml or 100 pg/ml IFN-α2, IFN-ω, or IFN-β. Plasma samples from ELISA-positive were diluted 1:10 in all tests. HEK293T cells were transfected with the dual luciferase system with IFN-sensitive response elements (ISRE) before treatment with type I IFNs with or without plasma from patients, and relative luciferase activity (RLA) was calculated by normalizing firefly luciferase activity against Renilla luciferase activity. An RLA of <15% the value for the mock treatment was considered to indicate that the antibodies were neutralizing (dashed line). (D) Age and sex distribution of patients with auto-Ab neutralizing IFN-α2 and/or IFN-ω (n = 10).

Discussion
We found that almost 5% of patients with critical influenza pneumonia studied internationally had auto-Abs neutralizing IFN-α2 alone or with IFN-ω. We showed that these auto-Abs neutralized 10 ng/ml or at least 100 pg/ml type I IFNs in plasma diluted 1:10. The population of patients with critical influenza pneumonia was significantly enriched in auto-Ab-positive cases relative to a small sample of individuals with mild influenza infection or a much larger sample of individuals from the general population. The neutralizing auto-Abs blocked the antiviral activity of 20 pg/ml IFN-α2 in A549 cells infected with IAV, even when diluted 1:1,000. They also blocked the antiviral activity of IFN-α2 in HAEs infected with IAV in vitro, further suggesting that the auto-Abs were detrimental in IAV-infected human RECs in vivo. We showed that auto-Abs neutralizing IFN-α2 alone or with IFN-ω were present in almost 5% of patients with life-threatening influenza pneumonia, including ~6% of patients <70 yr old, ~7% of men, and ~8% of men <70 yr old. Auto-Abs neutralizing type I IFNs can also underlie life-threatening COVID-19 pneumonia and severe adverse reactions to the live attenuated yellow fever virus vaccine (Pozzetto et al., 1984; Bastard et al., 2020, 2021a, 2021c; Casanova and Abel, 2021b, 2022; Goncalves et al., 2021; Lopez et al., 2021; Zhang et al., 2022). Notably, the discovery of AR inborn errors of
type I and III IFN immunity in patients with life-threatening influenza pneumonia (mutations of IRF7, STAT2, and IRF9; Ciancanelli et al., 2015; Hernandez et al., 2018; Lim et al., 2019; Freij et al., 2020) led to that of overlapping (IRF7) and other (IFNAR1) AR etiologies of critical COVID-19 pneumonia (Asano et al., 2021; Zhang et al., 2020b), and conversely, the discovery of AR IFNAR1 deficiency and auto-Abs against type I IFNs in patients with critical COVID-19 pneumonia (Bastard et al., 2020; Bastard et al., 2021a) led to that of auto-Abs against type I IFNs in patients with critical influenza. It is intriguing that the known patients with AR IFNAR1 or IFNAR2 deficiency did not suffer from critical influenza (Bastard et al., 2022a; Hernandez et al., 2019; Bastard et al., 2021b; Duncan et al., 2022; Duncan et al., 2015). This may reflect the small number of patients diagnosed, their previous viral illnesses (e.g., MMR disease), prompting influenza vaccination, and an ascertainment bias. Our findings suggest that IFNAR1- or IFNAR2-deficient patients may be prone to critical influenza.

The greater enrichment in patients with auto-Abs against type I IFNs among patients with critical COVID-19 than among those with critical influenza is also intriguing. Indeed, although individuals with auto-Ab neutralizing these type I IFNs are 3–12 times more likely overall to develop critical influenza pneumonia than the general population, the overall prevalence of these auto-Abs in patients with critical influenza pneumonia is close to 5%, a figure significantly lower than the 15% of critical COVID-19 pneumonia patients with these antibodies (Bastard et al., 2021a). This observation may reflect the higher virulence of SARS-CoV-2 than of seasonal influenza viruses in unvaccinated individuals. We can speculate that a value of 15% would have been found among patients with critical influenza due to the 1918 H1N1 virus or in other, more recent influenza pandemics (Reichert et al., 2012; Krammer et al., 2018). We can also speculate that the lower the induction of type I IFNs by the virus, the higher the virulence, and the greater the vulnerability of individuals with auto-Abs against type I IFNs or with IFNAR1 or IFNAR2 deficiencies or other inborn errors of type I IFN immunity (Chen et al., 2021). Moreover, previous anti-influenza vaccination or infections with one or more related influenza viruses may mitigate the clinical impact of infections with new viral strains, including those in patients with auto-Abs against type I IFNs. The age-stratified analysis of our data supports this hypothesis. Indeed, we showed an enrichment in auto-Ab–positive cases among patients <70 yr of age, but not in older patients. Auto-Abs against type I IFNs were found in only three sick children, consistent with previous observations that pathogenic auto-Abs against type I IFNs are rare in children (Bastard et al., 2021a). Moreover, a strong enrichment in auto-Ab–positive cases was observed for younger patients (<70 yr old), with an OR of ≈7–140 depending on the nature of the auto-Abs, but not for older patients. The same trend was observed in patients with critical COVID-19 pneumonia (Manry et al., 2022), suggesting that risk factors other than auto-Abs contribute to critical influenza in the elderly.

Finally, our data highlight the major impact of the nature and concentration of type I IFNs neutralized by circulating auto-Abs on the risk of developing critical influenza pneumonia, as previously shown for COVID-19 pneumonia (Bastard et al., 2021a). After adjustment for age and sex, patients with auto-Abs neutralizing high concentrations of both IFN-α2 and IFN-ω were found to have the highest risk of critical influenza pneumonia (OR = 139.9 in patients <70 yr old, OR = 11.7 for all ages), whereas patients with auto-Abs neutralizing low concentrations IFN-α presented a smaller increase in the risk of critical pneumonia (OR = 6.6 in patients <70 yr old, OR = 2.8 for all ages). We identified only one patient with auto-Abs neutralizing high concentrations of IFN-ω only, and such antibodies were also rare in patients with critical COVID-19 pneumonia (0.8%; Bastard et al., 2021a). We found no patients with auto-Abs neutralizing IFN-β only, whereas such antibodies were found in almost 1% of patients with critical COVID-19 pneumonia (Bastard et al., 2021a). All auto-Abs neutralizing type I IFNs also neutralize the other 12 subtypes of IFN-α, but auto-Abs neutralizing IFN-ω or IFN-β neutralize only a single subtype of IFN (Bastard et al., 2021a; Bastard et al., 2020), making it less likely that such antibodies underlie critical seasonal influenza. It would be interesting to screen patients with critical influenza for auto-Abs neutralizing type III IFNs. These auto-Abs might contribute to influenza and other severe viral infections, especially of the respiratory tract (Lim et al., 2019). Overall, auto-Abs neutralizing type I IFNs can underlie at least three severe viral diseases, with an apparently greater risk of critical COVID-19 pneumonia than of critical influenza, while the risk of yellow fever vaccine disease is more difficult to estimate, given the small number of patients tested. These auto-Abs may also underlie other viral diseases, including severe disease caused by the varicella zoster virus, as disseminated zoster was the clinical manifestation of the first patient with causal auto-Abs against type I IFN ever described, by Ion Gresser in 1984 (Pozzetto et al., 1984; Walter et al., 2015; Busnadio et al., 2022; Mathian et al., 2022).

Materials and methods

Patients
We recruited 279 patients from Belgium (31), Greece (5), Spain (40, including some cases described previously; Lopez-Rodriguez et al., 2016; Herrera-Ramos et al., 2014), Israel (1), and France (202) who had been hospitalized for critical influenza pneumonia, as defined by admission to an ICU for ARDS following a diagnosis of influenza and treatment with invasive or noninvasive mechanical ventilation or ECMO between 2012 and 2021. From the same clinical centers in Greece (24) and Spain (14), we recruited patients with mild influenza infections not requiring hospitalization during the same period. In addition, we recruited five other independent cohorts of 130 patients hospitalized for influenza pneumonia from Chile (82), Spain (45), France (1), Belgium (1), and Taiwan (1), including 84 patients requiring oxygen therapy (65%). All the patients were diagnosed with influenza infection by PCR. We previously tested 34,159 healthy men and women aged 20–100 yr to estimate the prevalence of auto-Abs neutralizing type I IFNs in the uninfected general population (Bastard et al., 2021a). We further tested 1,065 healthy children, 12 of whom (1.1%) were found to be
auto-Ab–positive (Bastard et al., 2022b). Written informed consent was obtained in the country of residence of the patients, in accordance with local regulations, and with institutional review board approval. Experiments were conducted in the United States, France, and Estonia in accordance with local regulations and with the approval of the institutional review board. Approval was obtained from the French Ethics Committee “Comité de Protection des Personnes,” the French National Agency for Medicine and Health Product Safety, the “Institut National de la Santé et de la Recherche Médicale,” in Paris, France (protocol no. C10-13), and the Rockefeller University Institutional Review Board in New York, NY (protocol no. JCA-0700). For the Chilean samples, clinical and epidemiological data and the corresponding clinical specimens were collected after informed written consent was obtained under protocol 16-066, which was reviewed and approved by the Scientific Ethics Committee for Health Sciences (CECSaludUC) at Pontificia Universidad Católica de Chile.

Luciferase reporter assays

The blocking activity of anti–IFN-α2 and anti–IFN-ω auto-Ab was determined with a reporter luciferase assay. Briefly, HEK293T cells were transfected with a plasmid containing the firefly luciferase gene under the control of the human ISRE promoter in the pGL4.45 backbone and a plasmid constitutively expressing the Renilla luciferase for normalization (pRL-SV40). Cells were transfected by incubation for 24 h with the plasmids and X-tremeGene9 transfection reagent (ref. number 6365779001; Sigma-Aldrich). Cells in DMEM (Thermo Fisher Scientific) supplemented with 2% FCS and 10% healthy control patient serum/plasma (after inactivation at 56°C, for 20 min) either were left unstimulated or were stimulated with IFN-α2 (ref. number 130-108-984; Miltenyi Biotec) or IFN-ω (ref. number SRF3061; Merck), at a concentration of 10 ng/ml or 100 μg/ml, or IFN-β (ref. number 130-107-888; Miltenyi Biotec) at 10 ng/ml, for 16 h at 37°C. Each sample was tested once for each cytokine and dose. Finally, cells were lysed for 20 min at room temperature, and luciferase levels were measured with the Dual-Luciferase Reporter 1000 assay system (ref. number E1980; Promega), according to the manufacturer’s protocol. Luminescence intensity was measured with a VICTOR-X Multilabel Plate Reader (PerkinElmer Life Sciences). Firefly luciferase activity values were normalized against Renilla luciferase activity values. These values were then normalized against the median induction level for nonneutralizing samples and expressed as a percentage. Samples were considered neutralizing if luciferase induction, normalized against Renilla luciferase activity, was <15% of the median value for controls tested the same day. For 35 patients whose plasma did not neutralize 100 pg/ml IFN-α2 or IFN-ω, we did not perform the neutralization assay with 10 ng/ml IFN-α2/ω due to the limited volume of plasma available.

Functional evaluation of IFN auto-Ab

A549 cells (CRM-CCL-185; ATCC) were cultured in DMEM (Gibco) supplemented with 10% FBS (PEAK) and penicillin-streptomycin (Gibco), at 37°C, under an atmosphere containing 5% CO2. Cells were tested periodically for mycoplasma contamination, with negative results in all cases.

A549 cells were used to seed 96-well plates at a density of 3 × 10^3 cells/well. The next day, a commercial anti–IFN-α2 antibody (catalog number 21100-1; R&D Systems) of plasma samples were serially diluted (10-fold) and incubated with 20 pg/ml recombinant IFN-α2 (catalog number 1101-2; R&D Systems) for 1 h at 37°C (starting concentration: plasma samples = 1/100 and anti–IFN-α2 antibody = 1/100). The cell culture medium was then removed from the 96-well plates and replaced with the plasma/antibody–IFN-α2 mixture. Each sample was tested once, in triplicate. The plates were incubated overnight, and the plasma/antibody–IFN-α2 mixture was removed by aspiration. The cells were then washed three times with PBS to remove potential anti-influenza neutralizing antibodies and infected with a recombinant Cal/09 virus expressing NS1-mCherry (CalNSmCherry) at a multiplicity of infection (MOI) of 0.5. 16 h after infection, cells were fixed with 4% formaldehyde, washed twice with PBS, and stained with DAPI. The percentage of infected cells was quantified with a Celigo (Nexcelcom) imaging cytometer.

HAE infection with IAV

Influenza seroneutralization assay in Madin-Darby canine kidney cells

Plasma samples were serially diluted in MEM (Lonza) supplemented with 2 mM L-glutamine (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco), and 1 μg/ml acetylated trypsin from bovine pancreas (Sigma-Aldrich). Serial dilutions were mixed with 100 TCID50 of A/Lyon/969/2009 H1N1 virus and incubated at 37°C for 1 h. We then inoculated 96-well plates containing confluent Madin-Darby canine kidney cells in 150 μl of supplemented MEM in quadruplicate with 50 μl per well of the plasma-virus dilutions and incubated the plates at 37°C, under an atmosphere containing 5% CO2. After 96 h of incubation, we checked for cytopathic effects by microscopy. The anti-influenza serumneutralization titer for each plasma sample is expressed as the inverse of the highest dilution at which no cytopathic effects were observed in at least two of the four wells.

Viral infection and IFN treatment in reconstructed HAE

MuclAir HAE reconstituted from human nasal primary cells (pool of 14 donors with no identified diseases) were provided by Epithelix SARL and maintained in an air–liquid interface at 37°C, under an atmosphere containing 5% CO2, in specific culture medium in Costar Transwell inserts according to the manufacturer’s instructions. The day before infection (day –1), HAE were mock-treated or treated via the basolateral pole with 2 ng recombinant IFN-α2a or 20 ng recombinant IFN-λ1/IL-29, IFN-λ2/IL-28A, or IFN-λ3/IL-28B (PBL Assay Science) in 700 μl MuclAir culture medium. We assessed the functional neutralizing effect of anti–IFN-1 antibodies, by incubating recombinant IFN-α2a, IFN-λ1/IL-29, IFN-λ2/IL-28A, or IFN-λ3/IL-28B (37°C, 1 h) with a 1% final dilution of inactivated (56°C, 30 min) patient plasma, containing or not containing anti–IFN-α antibodies, before addition to HAE. On the day after this IFN treatment, the apical poles of the HAE were gently washed twice with warm
OptiMEM (Gibco, Thermo Fisher Scientific) and infected with 150 μl of a dilution of A/Lyon/969/2009 H1N1 virus in OptiMEM, at an MOI of 0.1, in the presence or absence of plasma. Basolateral treatment with recombinant IFN (with or without plasma) was repeated 1 h after infection in the same conditions as on day −1. Changes in TEER were measured with a dedicated Volt-Ohm meter (EVOM2, Epithelial Volt/Ohm Meter) and expressed in Ohm/cm². At 54 h after infection, the apical poles of the HAE were washed with warm OptiMEM and collected in two tubes: one for TCID₅₀ determination and the other for viral genome quantification by quantitative RT-PCR. HAE cells were harvested in RLT buffer (Qiagen), and total RNA was extracted with the RNeasy Mini Kit (Qiagen), and total RNA was extracted with the RNeasy Mini Kit (Qiagen) for gene expression analyses.

Transcriptomic analyses in reconstituted HAE
We hybridized 200 ng total RNA from HAE cells with a customized 96-gene panel, with counting on an nCounter FLEX platform according to the manufacturer’s instructions. Table S1 provides more information about the panel and the genes analyzed. Data processing and normalization were performed with nSolver analysis software (v4.0; NanoString Technologies), and the results are expressed as a fold-change induction relative to mock (untreated/uninfected) conditions. A heatmap of gene expression profiles from unsupervised hierarchical clustering (Euclidean distance matrix with Ward’s method) was generated with Genomics Suite 7 (Partek).

ELISAs were performed as previously described (Puel et al., 2022). In brief, 96-well ELISA plates (MaxiSorp; Thermo Fisher Scientific) were coated by incubation overnight at 4°C with 2 μg/ml rhIFN-α and rhIFN-ω (R&D Systems). Plates were then washed (PBS/0.005% Tween), blocked by incubation with the same buffer supplemented with 5% nonfat milk powder, washed, and incubated with 1:50 dilutions of plasma samples from the patients or controls for 2 h at room temperature (or with specific mAbs as positive controls). Each sample was tested once. Plates were thoroughly washed. HRP-conjugated Fc-specific IgG fractions from polyclonal goat antisera against human IgG or IgA (Nordic Immunological Laboratories) were added to a final concentration of 2 μg/ml. Plates were incubated for 1 h at room temperature and washed. Substrate was added and OD was measured.

Statistical analysis
OR and P values for the effect of auto-Abs neutralizing each type I IFN on critical influenza relative to healthy individuals from the general population, adjusted for age in four categories (<16, 16 to <50, 50 to <70, and ≥70 yr) and sex, were estimated by means of Firth’s bias-corrected logistic regression (Firth, 1993; Heinze and Schemper, 2002), as implemented in the logist package of R software. We tested for an interaction between the effect of auto-Abs and age, by adding an age × auto-Abs interaction term to the logistic regression model, with age classified into two categories (<70 yr vs. ≥70 yr).

Table S1 provides more information about the panel and the genes analyzed.

Acknowledgments
We thank Dr. Cato Jacobs for her contribution to the sampling of UZLeuven patients in Belgium.

The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH; R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences, NIH Clinical and Translational Science Award program (UL1 TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (EUQ201903007798), the ANRS-COV5, ANRS-RHU program ANR-21-RHU-08, ANR GENVIR (ANR-20-CE93-003), ANR GenMISC (ANR-21-COV-0039), and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-ITHL-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir–Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, and the Université Paris Cité. This work was partly supported by the Center for Research on Influenza Pathogenesis and Transmission, a National Institute of Allergy and Infectious Diseases (NIAID)–funded Center of Excellence for Influenza Research and Response (contract no. 75N93021C00014), and the FLUOMICS Consortium (NIAID grant U19AI35972) to both A. García-Sastre and R.A. Medina, and by NIAID grant U19AI142733 and U19AI168631 to A. García-Sastre. Work in the Medina laboratory was also supported by the PIA ACT 1408, FONDECYT 1161971 and 1212023 grants from Agencia Nacional de Investigación y Desarrollo de Chile. The VirPath team is supported by INSERM REACTing (Research & Action Emerging Infectious Diseases), CNRS, and Mérieux Research grants. B. Padey is supported by an ANRT CIFRE PhD scholarship. For the Lyon cohort, specimen collection and study was supported by a grant from the French Ministry of Health PHRC-1 2013 ANTIGRIFFE. C. Rodríguez-Gallego and colleagues were supported by the Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI12/01565, Spanish Ministry for Science and Innovation RTC-2017-6471-1; AEI/ FEDER, UE), Grupo DISA, Fundación MAPFRE Guanarteme, Sociedad Española de Neuromlogía y Cirugía Torácica and Cabildo Insular de Tenerife (CGIEU000219140 and “Apuestas, científicas del Instituto Tecnológico y de Energías Renovables para colaborar en la lucha contra la COVID-19”). E. Andreakos is supported by the Hellenic Foundation for Research and...
Innovacion (INTERFLU, no. 1574). P. Bastard was supported by the French Foundation for Medical Research (EA20170638020) and by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schuller). This study was supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009); cofinanced by European Regional Development Fund “A way to achieve Europe”; Operative Program Intelligence Growth 2014-2020 (CB21/13/00006) also was supported by CIBER-Consortio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—Next Generation EU and Consejería de Economía, Conocimiento, Empresas y Universidad, Secretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía, Spain (P18-RT-3320). I. Meyts is a Senior Clinical Investigator at the Research Foundation-Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies, a CSL-Behring Research Grant, KU Leuven C1 grant C16/18/007, a VIB GC PID Grant, Fonds Wetenschappelijk Onderzoek grants G0C8517N, G0BS120N, and G0ES420N, and the Jeffrey Modell Foundation. Open Access funding provided by Rockefeller University.


Disclosures: A. Pizzorno reported a patent to WO2016/146836 licensed (Signia Therapeutics), a patent to WO2017/174593 licensed (Signia Therapeutics), and a patent to WO2019/224489 licensed (Signia Therapeutics); and is the co-founder of Signia Therapeutics SAS. N. Le Corre reported personal fees from SINOVAC outside the submitted work. P. Retamar-Gentil reported personal fees from Merck outside the submitted work. I. Meyts reported grants from CSL-Behring outside the submitted work. E. Andreaskos reported grants from Janssen Pharmaceuticals during the conduct of the study. J. Wauters reported grants and personal fees from Pfizer and Gilead outside the submitted work. L. Vanderbeke reported grants from Research Foundation Flanders and non-financial support from Pfizer outside the submitted work. S. Feys reported grants from Pfizer outside the submitted work. J. Casalegno reported "other" from Pfizer and grants from Sanofi outside the submitted work. M. Rosa-Calatrava reported a patent to WO2016/146836 licensed (Signia Therapeutics), a patent to WO2017/174593 licensed (Signia Therapeutics), and a patent to WO2019/224489 licensed (Signia Therapeutics); and is the co-founder of Signia Therapeutics SAS. S. Trouillet-Assant reported non-financial support from BioMérieux outside the submitted work. A. Garcia-Sastre reported "other" from Vivaldi Biosciences, Pagoda, Contrafect, Vaxalto, Accuriss, Curelab oncology, and Curelab veterinary; personal fees from Avimex, 7 Hills, Esperovax, Pfizer, Farmak, Applied Biological Laboratories, Paratus, Pharmamar, Pfizer, and Synairgen; grants from Pfizer, Pharmamar, Blade Therapeutics, Avimex, Accuriss, Dynavax, Kenall Manufacturing, ImmunityBio, Nanocomposix, Merck, Model Medicines, Atea Pharma, Shenwa Biosciences, Johnson & Johnson, 7 Hills, Hexamer, N-fold LLC, and Applied Biological Laboratories outside the submitted work; in addition, A. García-Sastre had a patent for influenza virus vaccines and uses thereof issued; and invited speaker in meeting events organized by Seqirus, Janssen, Abbott, and Astrazeneca. J. Casanova reported a patent to PCT/US2021/042741 pending. No other disclosures were reported.

Submitted: 22 March 2022
Revised: 4 July 2022
Accepted: 8 August 2022

References


Zhang et al. Autoantibodies to type I IFNs in severe influenza https://doi.org/10.1084/jem.20220514


Autoantibodies to type I IFNs in severe influenza

Zhang et al.

Journal of Experimental Medicine
https://doi.org/10.1084/jem.20220514

18 of 18


Supplemental material

Table S1 is provided online and lists more information about the panel and the genes analyzed.
COVID Human Genetic Effort


1Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France
2San Raffaele Telethon Institute for Gene Therapy, IRCCS Ospedale San Raffaele, and Vita Salute San Raffaele University, Milan, Italy
3Immunology Research Lab, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia
4Dasman Diabetes Institute, Department of Genetics and Bioinformatics, Dasman, Kuwait
5Diabetes Center, University of California San Francisco, San Francisco, CA
6Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
7St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY; Primary Immunodeficiencies Group, Department of
Microbiology and Parasitology, School of Medicine, University of Antioquia, Medellín, Colombia; School of Microbiology, University of Antioquia UdeA, Medellín, Colombia

8The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

9Pediatric Nephrology, Rheumatology, Dermatology, HFME, Hospices Civils de Lyon, National Referee Centre RAISE, and INSERM U1111, Université de Lyon, Lyon, France

10Department of Pediatrics, BC Children’s and St. Paul’s Hospitals, University of British Columbia, Vancouver, British Columbia, Canada

11Icahn School of Medicine at Mount Sinai, New York, NY

12Helix, San Mateo, CA

13Shupyk National Medical Academy for Postgraduate Education, Kiev, Ukraine

14Clinical Immunology Unit, Department of Pediatric Infectious Disease, CHU Ibn Rushd and LICIA, Laboratoire d’Immunologie Clinique, Inflammation et Allergie, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco

15SciLifeLab, Department Of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

16Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden

17Stanford University, Stanford, CA

18Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics and the Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA

19Clinical Genomics, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy

20Murdoch Children’s Research Institute and Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia

21Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

22de Duve Institute and Ludwig Cancer Research, Brussels, Belgium

23Washington University School of Medicine, St. Louis, MO

24Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD

25Bai Jerbai Wadia Hospital for Children, Mumbai, India
26 School of Medicine and Public Health, University of Wisconsin, Madison, WI
27 Genetics Unit, Military Hospital Mohamed V, Rabat, Morocco
28 Instituto Nacional de Pediatría (National Institute of Pediatrics), Mexico City, Mexico
29 School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
30 Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid; Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain
31 Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, “Attikon” University General Hospital, Athens, Greece
32 Group of Primary Immunodeficiencies, University of Antioquia UDEA, Medellin, Colombia
33 Pulmonology Department, Cliniques Universitaires Saint-Luc; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium
34 Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
35 Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY
36 Center for Chronic Immunodeficiency & Institute for Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
37 Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPIG), PID Research Laboratory, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium
38 The Genetics Institute Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
39 Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
40 Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden
41 Institute for Systems Biology, Seattle, WA
42 Department of Pediatrics, Division of Allergy Immunology, Children’s Hospital of Philadelphia, Philadelphia, PA; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
43 Departments of Pediatrics, Immunology and Microbiology, University of Colorado, School of Medicine, Aurora, CO
44 Department of Medicine, Haukeland University Hospital, Bergen, Norway
45 Department of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

46 Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

47 Laboratory of Neurogenetics of Language and Howard Hughes Medical Institute, The Rockefeller University, New York, NY

48 Bioinformatics and Applied Genomics Unit, Hellenic Pasteur Institute, Athens, Greece

49 Molecular Pathology, Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu Estonia

50 Second Respiratory Clinic, “Sotiria” General Hospital of Chest Diseases, Athens, Greece

51 Chang Gung University, Taoyuan County, Taiwan

52 Department of Paediatrics & Adolescent Medicine, The University of Hong Kong, Hong Kong, China

53 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

54 Department of Immunobiology, Yale University School of Medicine, New Haven, CT

55 Zukerman Mind Brain Behavior Institute, Columbia University, New York, NY

56 Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti, University of Medical Sciences, Tehran, Iran

57 Primary Immunodeficiency Clinical Unit and Laboratory, Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary

58 Department of Pediatrics, University Hospitals Leuven; KU Leuven, Department of Microbiology, Immunology and Transplantation; Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium

59 Department of Pediatrics, Columbia University Irving Medical Center, New York, NY

60 University Clinic for Children’s Diseases, Department of Pediatric Immunology, Medical Faculty, University “St. Cyril and Methodij” Skopje, North Macedonia

61 Department of Biomedicine, Aarhus University, Aarhus, Denmark

62 Tokyo Medical & Dental University Hospital, Tokyo, Japan

63 A*STAR Infectious Disease Labs, Agency for Science, Technology and Research, Singapore; Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore
64National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
65Laboratory of Medical Genetics, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
66Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy
67Comparative Immunology Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
68Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
69Tokyo Medical and Dental University, Tokyo, Japan
70Department of Molecular Biology and Genetics, Bilkent University, Bilkent—Ankara, Turkey
71Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden
72Haitian Study Group for Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti
73Institute of Biomedical Research of IdiPAZ, University Hospital “La Paz”, Madrid, Spain
74Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ
75Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari A. Moro, Bari, Italy
76IIBB-CSIC, IDIBAPS, Barcelona, Spain
77Faculdades Pequeno Príncipe, Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil
78Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain; Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain; Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain
79Human Evolutionary Genetics Unit, CNRS U2000, Institut Pasteur, Paris, France; Human Genomics and Evolution, Collège de France, Paris, France
80Al Jalila Children's Hospital, Dubai, United Arab Emirates
81Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, “Attikon” University General Hospital, Athens, Greece
82A*STAR Infectious Disease Labs, Agency for Science, Technology and Research, Singapore; Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore
83University Hospital St. Marina, Varna, Bulgaria
84Department of Immunology, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, Las Palmas de Gran Canaria; Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain

85ICU, First Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, “Sotiria” General Hospital of Chest Diseases, Athens, Greece

86Department of Paediatric Infectious Diseases and Virology, Imperial College London, London, UK; Centre for Paediatrics and Child Health, Faculty of Medicine, Imperial College London, London, UK

87Department of Immunology, Second Faculty of Medicine Charles University, V Uvalu, University Hospital in Motol, Prague, Czech Republic

88Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Rare Diseases Center and Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

89Specialized Immunology Laboratory of Dr. Shahrooei, Ahvaz, Iran; Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium

90Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

91Central European Institute of Technology & Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

92Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD

93Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain

94St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands

95Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria

96Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia

97Al Jalila Children’s Hospital, Dubai, United Arab Emirates

98Departments of Medical Genetics & Histology and Embryology, Faculty of Medicine; Department of Translational Medicine, Health Sciences Institute, Bursa Uludağ University, Bursa, Turkey
99Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, “Attikon” University General Hospital, Athens, Greece

100BC Children’s Hospital, The University of British Columbia, Vancouver, Canada

101Centre for Precision Therapeutics, Genetics & Genomic Medicine Centre, NeuroGen Children’s Healthcare and Lecturer, Holy Family Red Crescent Medical College Dhaka, Bangladesh

102College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE; Cellular Intelligence (Ci) Lab, GenomeArc Inc., Toronto, Ontario, Canada

103Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

104Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada; Infectious Disease Susceptibility Program, Research Institute, McGill University Health Centre, Montréal, Québec, Canada

105Department of Pediatric Pneumology, Immunology and Intensive Care, Charité Universitätsmedizin, Berlin University Hospital Center, Berlin, Germany; Labor Berlin GmbH, Department of Immunology, Berlin, Germany; Berlin Institutes of Health (BIH), Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany

106Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium

107Biosciences Institute, University of São Paulo, São Paulo, Brazil

108Molecular Biophysics Division, Faculty of Physics, A. Mickiewicz University, Poznań, Poland

109National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

110The Rockefeller University & Howard Hughes Medical Institute, New York, NY; Necker Hospital for Sick Children & INSERM, Paris, France
Etablissement Français du Sang Study Group

Pascal Morel¹, Pascale Richard¹, Brigitte Bonneaudau¹, Dorothée Canno², Pierre Gallian¹,³, Michel Jeanne⁴, Magali Perroquin⁴, Hind Hamzeh-Cognasse⁵,⁶, Fabrice Cognasse⁵,⁶, Pierre Tiberghien¹,⁷

¹Etablissement Français du Sang, La Plaine St-Denis, France
²Etablissement Français du Sang, Dijon, France
³Unité des Virus Émergents (Aix-Marseille Université, IRD 190, INSERM 1207), Marseille, France
⁴Etablissement Français du Sang, Bordeaux, France
⁵Etablissement Français du Sang, Saint-Etienne, France
⁶SAINBIOSE, INSERM, U1059, University of Lyon, Université Jean-Monnet-Saint-Etienne, France
⁷UMR RIGHT 1098 INSERM, Etablissement Français du Sang, Université de Franche-Comté, Besançon, France

Constances

Rachel Nadif¹, Marcel Goldberg², Anna Ozguler², Joseph Henny², Sylvie Lemonnier², Mireille Coeuret-Pellicer², Stéphane Le Got², Marie Zins²

¹Université de Paris-Saclay, UVSQ, Université Paris-Sud, INSERM, Equipe d'Epidémiologie Respiratoire Intégrative, INSERM CESP, Villejuif, France
²Université de Paris Cite, Université Paris Saclay, UVSQ, INSERM UMS11, Villejuif, France

3C-Dijon Study

Christophe Tzourio¹, Stéphanie Debette², Carole Dufouil¹, Aïcha Soumaré¹, Morgane Lachaize², Nathalie Fievet³, Amandine Flaig³

¹University of Bordeaux; Bordeaux Population Health Center, INSERM U1219, Bordeaux, France
²University of Bordeaux; Bordeaux Population Health Center, INSERM U1219; Bordeaux University Hospital, Department of Neurology, Institute of Neurodegenerative Diseases, Bordeaux, France
³Laboratoire d'Analyses Génomiques - Centre de Ressources Biologiques; Institut Pasteur de Lille, Lille, France
Cerba Healthcare Group
Fernando Martin¹, Souad Mehlal-Sedkaoui¹, Jérôme Sallette¹
¹Cerba Healthcare, Issy-les-Moulineaux, France

Lyon Antigripppe Working Group
Romain Hernu¹, Bruno Lina², Carole Schwebel³, Isabelle Wroblewski⁴, Patrice Morand⁵, Bertrand Souweine⁶, Benoit Boeuf⁷, Helene Peigue-Lafeuille⁸, Michael Darmon⁹, Hugues Patural¹⁰, Bruno Pozzetto¹¹, Jean Pierre Quenot¹², Benoit Colomb¹³, Pierre Pothier¹⁴, Alexandre Belot¹⁵
¹Medical intensive Care Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France
²Virology Departement, CNR des virus des infections Respiratoires, Institut des Agents Infectieux, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
³Medical intensive Care Department, Université de Grenoble-Alpes, Grenoble, France
⁴Pediatric Intensive Care Unit, Université de Grenoble-Alpes, Grenoble, France
⁵Virology Department, Université de Grenoble-Alpes, Grenoble, France
⁶Medical intensive Care Department, CHU Gabriel-Montpied, Clermont-Ferrand, France.
⁷Pediatric Intensive Care Unit, Centre Hospitalier Universitaire Estaing, Clermont Ferrand, France
⁸Virology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
⁹Medical intensive Care Department, CHU de Saint-Etienne, Saint-Etienne, France
¹⁰Neonatal Intensive Care Unit, Department of Pediatric Medicine, CHU de Saint-Etienne, Saint-Etienne, France
¹¹Department of Infectious Agents and Hygiene, CHU de Saint-Etienne, Saint-Etienne, France
¹²Medical intensive Care Department, University Hospital Dijon, Dijon, France
¹³Pediatric Intensive Care Unit, University Hospital Dijon, Dijon, France
¹⁴Virology Departement, University Hospital of Dijon, Dijon, France
¹⁵Pediatric Nephrology, Rheumatology, Dermatology, HFME, Hospices Civils de Lyon, National Referee Centre RAISE, and INSERM U1111, Université de Lyon, Lyon, France
REIPI FLU Working Group

Maria Abad Arranz1, Manuela Aguilar Guisado2, Ana Escoresca Ortega3, Rafaela Gallardo Ríos4, Laura Merino Díaz2, Maria Del Mar Muñoz Garcia5, Nieves Ramírez Duque6, Gloria María Romero Vázquez7, Maria Jose Sánchez Cordero3, Celia Salamanca Rivera2, Jordi Niubó8, Alexander Rombauts9, Nicolás Navarrete10, Laura Romero Oraa10, Virginia Palomo10

1Respiratory Diseases Unit University Hospital Virgen del Rocío, Spain

2Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital; Institute of Biomedicine of Seville (IBiS), CSIC/University of Sevilla, Sevilla, Spain; Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC; CB21/13/00009), Instituto de Salud Carlos III, Madrid, Spain

3Critical Care Unit, University Hospital Virgen del Rocío, Spain

4Emergency Medicine Unit, University Hospital Virgen del Rocío, Spain

5Los Bermejales Clinical Unit, Distrito de Atención Primaria, Sevilla, Spain

6Internal Medicine Unit, University Hospital Virgen del Rocío, Spain

7Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Spain

8Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC; CB21/13/00009), Instituto de Salud Carlos III, Madrid, Spain; Department of Clinical Microbiology, Bellvitge University Hospital, Barcelona, Spain

9Department of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

10Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocio University Hospital; Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC; CB21/13/00009), Institut de Salud Carlos III, Madrid, Spain; Infectious Diseases, Microbiology Unit, Virgen Macarena University Hospital, Seville, Spain